

FAX TRANSMITTAL
TO THE UNITED STATES PATENT OFFICE

APR 09 2004
OFFICIAL

Applicants Docket Number:
DEAV2003/0008 US NP

Applicants:
MICHAELIS, et al

Serial No.
10/773,772

Filing Date:
02/06/2004

Title of Invention:
THE USE OF ANTAGONISTS OF THE BRADYKININ B2 RECEPTOR FOR THE TREATMENT OF
OSTEOARTHRISIS

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted via
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450, at 703-872-9306, on

Date of Deposit April 9, 2004

Printed Name of Person Signing Certificate Paul Irvine

Signature

Total Number of Pages Sent: 4

Agent: Jiang Lin

Group Art Unit:
Examiner: Not Yet Known

TO: Mail Stop Patent Application
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet,
signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit
account (18-1982) in the name of Aventis Pharmaceuticals Inc.

- | | |
|--|--|
| <input type="checkbox"/> Amendment, 37 CFR _____ | <input type="checkbox"/> Fee Transmittal |
| <input type="checkbox"/> Charge deposit account, in duplicate | <input type="checkbox"/> Petition under 37 CFR _____ |
| <input type="checkbox"/> Extension of Time Petition | <input checked="" type="checkbox"/> Other <u>Supplemental Information</u>
<u>Disclosure Statement</u> |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input checked="" type="checkbox"/> Other <u>Substitute Form 1449</u> |
| <input type="checkbox"/> Maintenance Fee Transmittal | |

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this
telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

RECEIVED
CENTRAL FAX CENTER

APR 09 2004

OFFICIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re Application of
MICHAELIS, et al.

Examiner: Not Yet Assigned

Art Unit:

Application No.: 10/773,772

Filed: 02/06/2004


Title: THE USE OF ANTAGONISTS OF THE
BRADYKININ B2 RECEPTOR FOR THE
TREATMENT OF OSTEOARTHRISISSUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98Mail Stop Patent Application
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

- ☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,



Jiang Lin, Reg. No. 51,065
Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3582
Telefax (908) 231-2626

Aventis Docket No. DEAV2003/0008 US NP

